Obsidian Therapeutics
OBX
12.37
-0.84
-6.33%
Obsidian Therapeutics
US · OBX
#3403 by market cap
12.37
-0.84
-6.33%
Live - 5344 symbols - heartbeat 219s ago
· 2026-10-08 10:11
Pre-market
13.20
0.00%
After-hours
13.20
0.00%
- Market cap
- 763.82M
- P/E (TTM)i
- 19.02
- P/Bi
- 2.18
- EPSi
- 0.65
- Div yieldi
- 0.00%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on OBX?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 2 years
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | 18.07M | 19.55M |
| Research & development | 73.19M | 86.11M |
| Operating profit | -91.26M | -105.67M |
| Pretax profit | -83.11M | -100.61M |
| Tax | 0 | 0 |
| Net profit | -83.11M | -100.61M |
| Basic EPS | -1 | -2 |
| Diluted EPS | -1.35 | -1.63 |
| Line item | 2025-03 | 2026-03 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | 5.48M | 4.55M |
| Research & development | 21.13M | 15.73M |
| Operating profit | -26.60M | -20.28M |
| Pretax profit | -24.99M | -19.63M |
| Tax | 0 | 0 |
| Net profit | -24.99M | -19.63M |
| Basic EPS | 0 | 0 |
| Diluted EPS | -0.41 | -0.32 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 172.85M | 81.52M |
| Cash & ST investments | 168.27M | 80.49M |
| Inventory | -- | -- |
| Total assets | 183.71M | 88.58M |
| Total current liabilities | 16.09M | 15.36M |
| Short-term debt | 2.99M | 3.06M |
| Long-term debt | -- | -- |
| Total liabilities | 358,144,000.00 | 354,617,000.00 |
| Total equity | -174.43M | -266.04M |
| Retained earnings | -195.33M | -295.94M |
| Line item | 2025-03 | 2026-03 |
|---|---|---|
| Total current assets | -- | 64.04M |
| Cash & ST investments | -- | 58.76M |
| Inventory | -- | -- |
| Total assets | -- | 70.14M |
| Total current liabilities | -- | 15.23M |
| Short-term debt | -- | 2.53M |
| Long-term debt | -- | -- |
| Total liabilities | -- | 346,333,000.00 |
| Total equity | -- | -276.20M |
| Retained earnings | -- | -315.57M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -75.00M | -90.39M |
| Depreciation & amortization | 1.53M | 1.48M |
| Free cash flow | -75.78M | -90.47M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 50.77M | 41.41M |
| Line item | 2025-03 | 2026-03 |
|---|---|---|
| Operating cash flow | -24.37M | -22.01M |
| Depreciation & amortization | 378.00K | 340.00K |
| Free cash flow | -24.42M | -22.01M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 39.91M | 27.44M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -45.24 | -73.90 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 10.75 | 5.31 |
| Quick ratioi | 10.46 | 5.24 |
| Debt / assetsi | 3.71 | 4.84 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2026-03 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -- | -135.81 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | -- | 4.21 |
| Quick ratioi | -- | 3.86 |
| Debt / assetsi | -- | 5.14 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
Quote time 2026-10-08 10:11:19 · For reference only, not investment advice and not tailored to your situation.